These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 37549269)
21. Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer. Zhao Y; Tindall DJ; Huang H Int J Biol Sci; 2014; 10(6):614-9. PubMed ID: 24948874 [TBL] [Abstract][Full Text] [Related]
22. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Metzger E; Wissmann M; Yin N; Müller JM; Schneider R; Peters AH; Günther T; Buettner R; Schüle R Nature; 2005 Sep; 437(7057):436-9. PubMed ID: 16079795 [TBL] [Abstract][Full Text] [Related]
23. [Research Progress of Role and Mechanism of SETD7 in Tumor Occurrence and Progression]. Cao L; Wang M; Xu K Zhongguo Fei Ai Za Zhi; 2023 Jan; 26(1):38-45. PubMed ID: 36792079 [TBL] [Abstract][Full Text] [Related]
24. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372 [TBL] [Abstract][Full Text] [Related]
25. LSD1 dual function in mediating epigenetic corruption of the vitamin D signaling in prostate cancer. Battaglia S; Karasik E; Gillard B; Williams J; Winchester T; Moser MT; Smiraglia DJ; Foster BA Clin Epigenetics; 2017; 9():82. PubMed ID: 28811844 [TBL] [Abstract][Full Text] [Related]
26. Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer. Tam KJ; Liu L; Hsing M; Dalal K; Thaper D; McConeghy B; Yenki P; Bhasin S; Peacock JW; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ Sci Rep; 2024 Mar; 14(1):7082. PubMed ID: 38528115 [TBL] [Abstract][Full Text] [Related]
27. Targeting INMT and interrupting its methylation pathway for the treatment of castration resistant prostate cancer. Zhong S; Jeong JH; Huang C; Chen X; Dickinson SI; Dhillon J; Yang L; Luo JL J Exp Clin Cancer Res; 2021 Sep; 40(1):307. PubMed ID: 34587977 [TBL] [Abstract][Full Text] [Related]
28. FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A. Wang X; Brea L; Lu X; Gritsina G; Park SH; Xie W; Zhao JC; Yu J Oncogene; 2022 Sep; 41(37):4259-4270. PubMed ID: 35931888 [TBL] [Abstract][Full Text] [Related]
30. Substrate docking-mediated specific and efficient lysine methylation by the SET domain-containing histone methyltransferase SETD7. Liu H; Li Z; Yang Q; Liu W; Wan J; Li J; Zhang M J Biol Chem; 2019 Sep; 294(36):13355-13365. PubMed ID: 31324717 [TBL] [Abstract][Full Text] [Related]
31. SETD7 Promotes Cell Proliferation and Migration via Methylation-mediated TAF7 in Clear Cell Renal Cell Carcinoma. Zhang J; Duan B; Li F; Jing X; Li R; Cai S; Cao L; Jiang Q; Zhou J; Zhou J; Qin Y; Wang X; Tong D; Huang C Int J Biol Sci; 2024; 20(8):3008-3027. PubMed ID: 38904013 [TBL] [Abstract][Full Text] [Related]
32. Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics. Chianese U; Papulino C; Passaro E; Evers TM; Babaei M; Toraldo A; De Marchi T; Niméus E; Carafa V; Nicoletti MM; Del Gaudio N; Iaccarino N; Randazzo A; Rotili D; Mai A; Cappabianca S; Mashaghi A; Ciardiello F; Altucci L; Benedetti R Mol Metab; 2022 Oct; 64():101561. PubMed ID: 35944897 [TBL] [Abstract][Full Text] [Related]
33. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. Krause WC; Shafi AA; Nakka M; Weigel NL Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967 [TBL] [Abstract][Full Text] [Related]
34. FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway. Imamura Y; Sakamoto S; Endo T; Utsumi T; Fuse M; Suyama T; Kawamura K; Imamoto T; Yano K; Uzawa K; Nihei N; Suzuki H; Mizokami A; Ueda T; Seki N; Tanzawa H; Ichikawa T PLoS One; 2012; 7(8):e42456. PubMed ID: 22879989 [TBL] [Abstract][Full Text] [Related]
35. Molecular basis for substrate recognition by lysine methyltransferases and demethylases. Del Rizzo PA; Trievel RC Biochim Biophys Acta; 2014 Dec; 1839(12):1404-15. PubMed ID: 24946978 [TBL] [Abstract][Full Text] [Related]
36. CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies. Hwang JH; Arafeh R; Seo JH; Baca SC; Ludwig M; Arnoff TE; Sawyer L; Richter C; Tape S; Bergom HE; McSweeney S; Rennhack JP; Klingenberg SA; Cheung ATM; Kwon J; So J; Kregel S; Van Allen EM; Drake JM; Freedman ML; Hahn WC Elife; 2022 May; 11():. PubMed ID: 35550030 [TBL] [Abstract][Full Text] [Related]
37. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448 [TBL] [Abstract][Full Text] [Related]
38. Emerging roles of lysine methylation on non-histone proteins. Zhang X; Huang Y; Shi X Cell Mol Life Sci; 2015 Nov; 72(22):4257-72. PubMed ID: 26227335 [TBL] [Abstract][Full Text] [Related]
39. Lysine N-methyltransferase SETD7 promotes bladder cancer progression and immune escape via STAT3/PD-L1 cascade. Lv J; Wu Q; Li K; Bai K; Yu H; Zhuang J; Sun H; Yang H; Yang X; Lu Q Int J Biol Sci; 2023; 19(12):3744-3761. PubMed ID: 37564199 [No Abstract] [Full Text] [Related]
40. The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion. Wang J; Yu Q; Qiu Z; Dai T; Wang S; Yang X; Evers BM; Wu Y Aging (Albany NY); 2020 Jan; 12(1):397-415. PubMed ID: 31901895 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]